Health and Healthcare

Oracle Buys Drug Trial Software Firm (ORCL)

Oracle Corp. (NASDAQ: ORCL) has announced that it will acquire ClearTrial, a maker of cloud-based Clinical Trial Operations applications for an undisclosed sum. The transaction is expected to close in the first half of this year. The companies will continue to operate separately until the transaction is closed according to the Oracle announcement.

ClearTrial’s clinical trial applications “will add leading budgeting, forecasting, and analytics capabilities that help plan, source, and track clinical projects,” according to an Oracle overview of the transaction. Oracle plans to integrate ClearTrial’s solutions into its Health Sciences applications portfolio.

Oracle shares are trading down fractionally at $29.34 in a 52-week range of $24.72-$36.50.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.